Press release
Neuroendocrine Tumors Pipeline Assessment, 2024 Updates | In-depth Insights into Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Pfizer, Takeda Oncology, Hutchison
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Neuroendocrine Tumors pipeline constitutes 55+ key companies continuously working towards developing 60+ Neuroendocrine Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.The Neuroendocrine Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Neuroendocrine Tumors Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroendocrine Tumors Market.
Some of the key takeaways from the Neuroendocrine Tumors Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Neuroendocrine Tumors treatment therapies with a considerable amount of success over the years.
*
Neuroendocrine Tumors companies working in the treatment market are Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others, are developing therapies for the Neuroendocrine Tumors treatment
*
Emerging Neuroendocrine Tumors therapies in the different phases of clinical trials are- ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others are expected to have a significant impact on the Neuroendocrine Tumors market in the coming years.
*
In May 2023, Amgen commenced a Phase III study involving tarlatamab versus standard of care for individuals experiencing relapsed small cell lung cancer after initial platinum-based chemotherapy. This trial is actively enrolling participants and is projected to conclude by June 2025, aiming for an estimated enrollment of 700 participants.
*
In March 2023, RayzeBio, Inc., a company focused on targeted radiopharmaceuticals for solid tumors, reported the conclusion of enrollment for the Phase 1b segment within the ACTION-1 Phase 1b/3 trial evaluating RYZ101. This trial involves patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who experienced progression after receiving Lutetium-177 labeled somatostatin analog therapy.
*
In March 2023, NUCLIDIUM revealed that the Neuroendocrine Tumors Research Foundation ("NETRF") has chosen the company along with its collaborative partner, the University Hospital Basel (Universitatsspital Basel, "USB"), as recipients of its Investigator Award. This funding will aid in commencing and conducting a Phase 1 clinical trial featuring TraceNETTM, an innovative copper-based radiodiagnostic tool designed for detecting neuroendocrine tumors (NET).
Neuroendocrine Tumors Overview
Neuroendocrine tumors (NETs) are a diverse group of tumors that originate from neuroendocrine cells. These cells are found throughout the body, particularly in organs such as the gastrointestinal tract, pancreas, lungs, and adrenal glands. Neuroendocrine cells have characteristics of both nerve cells and hormone-producing cells, hence the name.
Get a Free Sample PDF Report to know more about Neuroendocrine Tumors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight [https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Neuroendocrine Tumors Drugs Under Different Phases of Clinical Development Include:
*
ITI 3000: Immunomic Therapeutics
*
Paltusotine: Crinetics Pharmaceuticals
*
PM8002: Biotheus
*
GP-2250: Panavance Therapeutics
*
BG-P-TAT: Nano Pharmaceuticals
*
OBT-620: Oxford BioTherapeutics
*
SVV-001: Seneca Therapeutics
*
Tarlatamab: Amgen
*
PNT2003: POINT Biopharma
*
RYZ101: RayzeBio
Neuroendocrine Tumors Route of Administration
Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical.
Neuroendocrine Tumors Molecule Type
Neuroendocrine Tumors Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Neuroendocrine Tumors Pipeline Therapeutics Assessment
*
Neuroendocrine Tumors Assessment by Product Type
*
Neuroendocrine Tumors By Stage and Product Type
*
Neuroendocrine Tumors Assessment by Route of Administration
*
Neuroendocrine Tumors By Stage and Route of Administration
*
Neuroendocrine Tumors Assessment by Molecule Type
*
Neuroendocrine Tumors by Stage and Molecule Type
DelveInsight's Neuroendocrine Tumors Report covers around 60+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Neuroendocrine Tumors product details are provided in the report. Download the Neuroendocrine Tumors pipeline report to learn more about the emerging Neuroendocrine Tumors therapies [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Neuroendocrine Tumors Therapeutics Market include:
Key companies developing therapies for Neuroendocrine Tumors are - Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.
Neuroendocrine Tumors Pipeline Analysis:
The Neuroendocrine Tumors pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
*
Neuroendocrine Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Neuroendocrine Tumors drugs and therapies [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Neuroendocrine Tumors Pipeline Market Drivers
*
Rising prevalence of the disease, growing Research and Development Activities are some of the important factors that are fueling the Neuroendocrine Tumors Market.
Neuroendocrine Tumors Pipeline Market Barriers
*
However, limited Awareness and Under diagnosis, heterogeneity and Complexity and other factors are creating obstacles in the Neuroendocrine Tumors Market growth.
Scope of Neuroendocrine Tumors Pipeline Drug Insight
*
Coverage: Global
*
Key Neuroendocrine Tumors Companies: Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others
*
Key Neuroendocrine Tumors Therapies: ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others
*
Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and Neuroendocrine Tumors emerging therapies
*
Neuroendocrine Tumors Market Dynamics: Neuroendocrine Tumors market drivers and Neuroendocrine Tumors market barriers
Request for Sample PDF Report for Neuroendocrine Tumors Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Neuroendocrine Tumors Report Introduction
2. Neuroendocrine Tumors Executive Summary
3. Neuroendocrine Tumors Overview
4. Neuroendocrine Tumors- Analytical Perspective In-depth Commercial Assessment
5. Neuroendocrine Tumors Pipeline Therapeutics
6. Neuroendocrine Tumors Late Stage Products (Phase II/III)
7. Neuroendocrine Tumors Mid Stage Products (Phase II)
8. Neuroendocrine Tumors Early Stage Products (Phase I)
9. Neuroendocrine Tumors Preclinical Stage Products
10. Neuroendocrine Tumors Therapeutics Assessment
11. Neuroendocrine Tumors Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Neuroendocrine Tumors Key Companies
14. Neuroendocrine Tumors Key Products
15. Neuroendocrine Tumors Unmet Needs
16 . Neuroendocrine Tumors Market Drivers and Barriers
17. Neuroendocrine Tumors Future Perspectives and Conclusion
18. Neuroendocrine Tumors Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuroendocrine-tumors-pipeline-assessment-2024-updates-indepth-insights-into-latest-fda-ema-and-pmda-approvals-clinical-trials-and-treatment-outlook-pfizer-takeda-oncology-hutchison]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuroendocrine Tumors Pipeline Assessment, 2024 Updates | In-depth Insights into Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Pfizer, Takeda Oncology, Hutchison here
News-ID: 3506585 • Views: …
More Releases from ABNewswire

Shashishekhar Ramagundam: Driving Innovation in AI and Content Discovery at ORCI …
Image: https://www.abnewswire.com/upload/2025/10/be0969e168c2d58f071b39a1d5c5c91e.jpg
Shashishekhar Ramagundam [https://www.linkedin.com/in/shashishekhar-ramagundam-051a1233b] is a computer scientist and senior IEEE member whose career has centered on advancing Machine Learning, artificial intelligence (AI) and scalable content delivery. His research and professional responsibilities directly address critical challenges in streaming media, recommendations, and enterprise-level data security, impacting both academic progress and industry practices.
Educational and Professional Background
Ramagundam earned a master's degree in computer science from Troy University, Alabama, in 2014, with academic strengths…

Conceivable's Proven Fertility Platform Delivers 260% Increase in Natural Concep …
Conceivable, the comprehensive women's health technology platform, has demonstrated remarkable clinical results with its virtual care approach, increasing the likelihood of natural conception by 260% for couples struggling with infertility. The company's integrated model combines fertility coaching, nutrition, culinary support, mental health services, and data science to address the root causes of infertility through personalized, evidence-based interventions.
Conceivable is revolutionizing fertility care with a virtual platform that has achieved what many…

WellnessLifeClub74 Launches Revolutionary E-Commerce Platform with Exclusive Bun …
New retail platform WellnessLifeClub74 debuts with an extensive collection of home essentials, trending gadgets, and hard-to-find items, offering unprecedented savings through innovative bundle packages. The company's unique VIP customer treatment program and curated selection of furniture, home decor, and wellness products are transforming the online shopping experience for discerning consumers.
WellnessLifeClub74 has officially entered the e-commerce marketplace with a comprehensive platform that combines extensive product selection with personalized customer service typically…

Intention Boutique Revolutionizes E-Commerce Through Live-Vetted Sellers and Val …
Innovative retail platform Intention Boutique challenges mass marketplace conventions by personally vetting every seller through live conversations-prioritizing authenticity and ethics over scale. The curated alternative serves intentional shoppers seeking transparency, non-toxic products, and purpose-driven commerce that honors small-batch craftsmanship.
Revolutionary thinking in e-commerce emerges as Intention Boutique Inc demonstrates how values-driven marketplace models can successfully challenge mass retail conventions through authentic seller relationships and intentional commerce standards. The innovative platform addresses…
More Releases for Neuroendocrine
Neuroendocrine Carcinoma Market Massive Growth opportunity Ahead
Introduction
Neuroendocrine carcinoma (NEC) is a rare and aggressive form of cancer that arises from neuroendocrine cells, which are found throughout the body and are responsible for producing hormones. These tumors can occur in various organs, including the lungs, pancreas, liver, and gastrointestinal tract. Due to its often vague and non-specific symptoms, neuroendocrine carcinoma is frequently diagnosed at an advanced stage, making it challenging to treat effectively.
In recent years, however, there…
Rising Neuroendocrine Tumors Fuel Treatment Market Growth Driving Market Acceler …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Neuroendocrine Tumor Treatment Market Size By 2025?
The industry for treating neuroendocrine tumors has witnessed substantial growth in the previous years. The market size is projected to escalate from $2.17 billion in 2024 to $2.4 billion in 2025, with a compound annual growth rate (CAGR)…
Emerging Trends Influencing The Growth Of The Neuroendocrine Tumor Treatment Mar …
The Neuroendocrine Tumor Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Neuroendocrine Tumor Treatment Market Size Expected to Be by 2034?
The market for neuroendocrine tumor treatment has seen a significant expansion in recent years. Projected to grow from a value…
Prominent Neuroendocrine Tumor Treatment Market Trend for 2025: Clinical Trials …
How Are the key drivers contributing to the expansion of the neuroendocrine tumor treatment market?
The neuroendocrine tumor treatment market is forecasted to expand due to the increasing incidence of neuroendocrine tumors. Neuroendocrine tumors, or NETs, are rare growths that begin in neuroendocrine cells, and their treatment is vital to managing the symptoms, controlling the tumor's growth, and applying radiation therapy to destroy the cancerous cells. The American Society of Clinical…
Neuroendocrine Tumor Treatment Market – Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% between 2021 to 2026. High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise…
Neuroendocrine Cancer Market: Rising Prevalence of Neuroendocrine Cancer and Gro …
The market report titled ‘Global Neuroendocrine Cancer Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.
Neuroendocrine Cancer Market Segmentation Analysis
Total Neuroendocrine Cancer Studies: 2499
By Drug Type
Everolimus
Sunitinib Malate
Lanreotide
Octreotide
Others
Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of…